Kolexia
Follana Philippe Oncologie médicale
Follana Philippe
Oncologie médicale
Centre Antoine Lacassagne
Nice, France
147 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Carcinome épithélial de l'ovaire Tumeurs du sein Récidive tumorale locale Carcinomes Tumeurs du poumon Tumeurs du pancréas Tumeurs de l'endomètre Adénocarcinome

Collaborateurs

Voir plus
Joly Florence
Joly Florence
Hôpital Côte de Nacre, Caen, France
Floquet Anne
Floquet Anne
Institut Bergonié, Bordeaux, France
Fabbro Michel
Fabbro Michel
Icm Montpellier, Montpellier, France
Kalbacher Elsa
Kalbacher Elsa
Centre Jean-Perrin, Clermont-Ferrand, France

Industries

Voir plus
GSK
28 collaboration(s)
Dernière en 2023
MSD
13 collaboration(s)
Dernière en 2023
Lilly
12 collaboration(s)
Dernière en 2023
B3TSI
10 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
BEATcc: A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Essai Clinique (Grupo Español de Investigación en Cáncer de Ovario)   04 mars 2024
DOMENICA: Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting
Essai Clinique (GSK)   28 février 2024
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecologic oncology   06 février 2024
A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial.
Future oncology (London, England)   22 janvier 2024
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Lancet (London, England)   01 décembre 2023
793P Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
CHIVA: Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer: Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy With the Bevacizumab + Taxane Versus Bevacizumab + Substituting Exemestane in Patients With Metastatic Breast Cancer or Locally Advanced With Estrogen Receptor Positive and Having at Least a Stable Disease After 16 to 18 Weeks of Treatment With Bevacizumab + Taxane.
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
Real-world dostarlimab use in advanced/recurrent endometrial cancer in France.
Bulletin du cancer   31 août 2023
GARNET: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Essai Clinique (Tesaro)   18 août 2023